Last Update 09 Aug 26
Fair value Increased 8.61%AIP: AI Data Center Licensing Strength Will Drive Earlier Royalty Upside
Analysts raised Arteris' fair value estimate from $37.75 to $41.00, reflecting higher Street price targets around $40, along with expectations for stronger AI driven interconnect IP demand and earlier royalty contributions from data center related licenses.
Analyst Commentary
Street research on Arteris has centered on how its interconnect IP and automation software are positioned against rising data movement needs in AI, automotive, and data center chips. Analysts have focused on the mix of licensing growth, the timing of royalty revenue, and the visibility of profit inflection when assessing valuation and risk.
Bullish Takeaways
- Bullish analysts highlight Arteris as a provider of system IP that helps customers handle complex system on chip designs. They see this positioning as supportive of long term licensing demand tied to increasing data movement requirements.
- Several research notes point to AI driven interconnect IP demand as a key support for licensing growth and potential share gains versus in house network on chip solutions. This view underpins higher price targets clustered around US$38 to US$40.
- Recent commentary cites data center and AI as the largest licensing vertical, with data center related licenses expected to bring in royalties earlier than automotive. This timing is viewed as helpful for nearer term revenue and cash flow visibility.
- Some bullish analysts refer to high operating leverage, strong financial visibility, and switching costs in Arteris' ecosystem as factors that could support future profit inflection and justify premium valuation multiples.
Bearish Takeaways
- More cautious analysts acknowledge improved royalty trends and AI related demand, yet highlight limited clarity on the path to sustained profitability after higher spending. They prefer more evidence on margins before getting more positive on the stock.
- There is an emphasis on execution risk around converting a growing pipeline of data center and AI design wins into mass production royalties. Any delay in these cycles could affect the pace of royalty growth relative to Street expectations.
- One research view keeps a neutral stance despite raising the price target. This signals concern that recent share performance and optimistic forecasts may already capture much of the growth case in current valuation.
- Analysts also flag dependence on a few high growth verticals such as data center and automotive. This concentration means slower activity or design cycles in these end markets could weigh on Arteris' revenue trajectory.
What’s in the News for Arteris
- Arteris reported second quarter 2026 financial results with Annual Contract Value plus royalties exiting the quarter at US$99.5 million, described in company materials as a record level and 44% higher year over year, and highlighted strong customer design activity in AI compute and AI infrastructure deals. Source: company earnings announcement.
- The company issued estimated guidance for the third quarter of 2026 and updated full year 2026 guidance. Management expects third quarter revenue of US$24.0 million to US$25.0 million and full year 2026 revenue of US$95.0 million to US$98.0 million. Source: company guidance update.
- Arteris announced an expanded partnership with Arm, which is adopting the Cycuity Radix hardware security assurance product across additional next generation processor programs to support security verification and analysis for CPU designs. Source: client announcement.
- Arteris disclosed a collaboration with IC-Link by imec to use Arteris NoC IP in reference designs that aim to simplify and accelerate development of next generation AI and high performance computing chiplets and ASICs. Source: product related announcement.
- Recent client announcements included SiEngine Technology licensing FlexNoC interconnect IP for its next generation automotive SoC platform and Li Auto using FlexNoC 5 and Magillem software in its L9 Livis SUV SoCs for AI compute and functional safety requirements. Source: client announcements.
Valuation Changes for Arteris
- Fair Value has risen from $37.75 to $41.00, an increase of around 9% that brings the estimate closer to recent Street price targets around $40.
- The Discount Rate has edged down slightly from 8.57% to about 8.54%, which provides a modest lift to the updated fair value estimate for Arteris.
- Revenue Growth has been trimmed from about 25.28% to roughly 24.51%, reflecting a slightly more conservative outlook for dollar revenue expansion in the model.
- Net Profit Margin has been adjusted from approximately 12.11% to about 11.34%, implying a more cautious view on future dollar earnings relative to sales.
- Future P/E has increased from about 147.6x to roughly 169.8x, which points to a higher valuation multiple being applied in the updated assumptions.
Key Takeaways
- Rising AI adoption and industry shifts toward chiplet architectures are expanding Arteris' market opportunities and supporting sustained revenue growth.
- Innovative product launches and stronger customer reliance are boosting competitive advantage, recurring revenues, and margin expansion potential.
- Dependence on large customers, rising R&D costs, and evolving industry dynamics threaten revenue stability, profitability, and long-term growth amid ongoing macroeconomic uncertainties.
Catalysts
About Arteris- Provides semiconductor system intellectual property solutions in the United States, rest of the Americas, China, Korea, the rest of the Asia Pacific, Europe, and the Middle East.
- Accelerating adoption of AI and machine learning in enterprise computing and automotive sectors is driving higher demand for Arteris' advanced NoC IP, as evidenced by recent major wins like AMD and Whalechip; this is likely to underpin sustained revenue growth as AI workloads and system complexity proliferate across industries.
- The ongoing industry transition to chiplet-based and heterogeneous integration architectures is expanding Arteris' addressable market, with chiplet-related design starts expected to rise from 5% to 30% in coming years; this structural trend supports both higher sales volume and increased average selling prices, benefiting future top-line revenue.
- Arteris' launch of innovative products such as FlexGen and Magillem Packaging-recognized with industry awards and integrated into leading chipmaker portfolios-raises the technological moat, improving competitive positioning and enabling potential margin expansion through pricing power.
- Increasing reliance by large semiconductor companies on outsourcing specialized system IP, highlighted by growing customer interest and accelerated engagements, suggests expanding recurring revenue streams and enhanced revenue visibility, which may drive more stable and predictable long-term earnings.
- Growth in remaining performance obligations (RPO), up 28% year-over-year, signals a solid and expanding contractual revenue base, providing confidence in forward revenue realization and supporting operating leverage as R&D investments start to scale with increased deployment of Arteris' solutions.
Arteris Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Arteris's revenue will grow by 24.5% annually over the next 3 years.
- Analysts are not forecasting that Arteris will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Arteris's profit margin will increase from -46.7% to the average US Software industry of 11.3% in 3 years.
- If Arteris's profit margin were to converge on the industry average, you could expect earnings to reach $18.5 million (and earnings per share of $0.31) by about August 2029, up from -$39.5 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $29.1 million in earnings, and the most bearish expecting $-20.0 million.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 170.1x on those 2029 earnings, up from -37.0x today. This future PE is greater than the current PE for the US Software industry at 32.5x.
- Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.54%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Arteris continues to operate at a net loss and projects a non-GAAP operating loss for the full year 2025 ($10.5 to $15.5 million), indicating ongoing challenges in achieving profitability and potential pressure on earnings and net margins if revenue growth falters or costs escalate.
- The high concentration of large whale deals (such as the recent AMD agreement) exposes Arteris to customer concentration risk; if major customers reduce outsourcing, insource NoC IP, or switch providers, future revenues and cash flows could become volatile.
- The increasing scale of R&D and field engineering investments, combined with only a gradual ramp in new product adoption, raises the risk that operating costs will outpace revenue growth, which could further suppress margins and delay a path to sustainable earnings.
- The expansion of chiplet and heterogeneous integration technologies by mega-customers (like AMD using its own Infinity Fabric for coherent data, and only using Arteris for non-coherent applications) could lead to competitors or major chipmakers developing proprietary NoC solutions, diminishing Arteris' external market and negatively impacting long-term revenue growth.
- Macroeconomic uncertainty (including FX fluctuations, global economic conditions, and possible geopolitical headwinds) can impact deal flow, OpEx (as seen recently with unfavorable USD/EUR movements), and delay sales cycles, all of which add risk to revenue predictability and margin expansion over time.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $41.0 for Arteris based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $50.0, and the most bearish reporting a price target of just $38.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $163.3 million, earnings will come to $18.5 million, and it would be trading on a PE ratio of 170.1x, assuming you use a discount rate of 8.5%.
- Given the current share price of $29.78, the analyst price target of $41.0 is 27.4% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Arteris?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.